Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sprung

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Diabetes, Obesity & Metabolism|September 5, 2023
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)Surya Panicker Rajeev, Carl Alexander Roberts, Emily Brown, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|June 21, 2014
Exercise training and artery function in humans: nonresponse and its relationship to cardiovascular risk factorsDaniel J Green, Thijs Eijsvogels, Yvette M Bouts, et al.
BMJ Open|March 26, 2025
Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and CanadaKatie Hesketh, Jonathan Low, Robert Andrews, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC)F O Mildner, M M Sykora, H Hackl, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Diabetes, Obesity & Metabolism|September 5, 2023
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)Surya Panicker Rajeev, Carl Alexander Roberts, Emily Brown, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|June 21, 2014
Exercise training and artery function in humans: nonresponse and its relationship to cardiovascular risk factorsDaniel J Green, Thijs Eijsvogels, Yvette M Bouts, et al.
BMJ Open|March 26, 2025
Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and CanadaKatie Hesketh, Jonathan Low, Robert Andrews, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC)F O Mildner, M M Sykora, H Hackl, et al.
Pageof 5